Overall verdict
Neutral
5.6/10
1-year performance
+24.67%
Score breakdown
Up 24.7% over 1 year, 57% of the 52-week range.
Strongest: Shareholder return 9.7/10. Weakest: Growth 2.9/10.
14 analysts, target +0.1% vs the price.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems ;
IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system ; hemodynamic monitoring system ; and prefillable drug delivery systems. It also offers specimen and blood collection products ;
automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products ; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Thomas Polen
Founded
1897
Employees
72 000
Revenue / employee
303 333 USD
Next earnings
November 5, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.99%
- VANGUARD CAPITAL MANAGEMENT LLC6.57%
- STATE STREET CORP5.48%
- VANGUARD PORTFOLIO MANAGEMENT LLC5.47%
- First Eagle Investment Management, LLC5.05%
- Invesco Ltd.3.25%
- GEODE CAPITAL MANAGEMENT, LLC2.98%
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/2.74%
- FRANKLIN RESOURCES INC2.56%
- Other institutions52.81%
- Rest of the register4.10%
1436 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
213.08 USD
52-week low
140.11 USD
1-year performance
24.67%
Rising
Year-to-date performance
19.54%
Rising
Drawdown
-14.73%
Mild pullback
Position in the 52-week range
57% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 1.6 times harder.
10,000 € placed at the end of September 2009 are worth today
| Becton Dickinson and | 59 129 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.6 times as much as the world ETF.
- Worst fall:-42 % between August 2023 and May 2025. 10,000 € placed at the top fell to 5 753 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Becton Dickinson and earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Becton Dickinson and: 59 129 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 170.00 USD - 178.38 USD (3 methods agree)
The price implies growth of 4.75% per year; the company grows at 16.45%.
Gross margin 46.4%, net margin 6.2%, ROIC 3.2%, ROE 5.2%.
Net margin
6.19%
Fair
Sector 8.49%|S&P 12.97%
Gross margin
46.44%
Fair
Return on equity (ROE)
5.17%
Fair
Sector 7.22%|S&P 16.52%
Return on invested capital (ROIC)
3.19%
Low
Free cash flow margin (FCF)
12.16%
High
Profit-to-cash conversion (FCF conversion)
1.97x
Exceptional
Margin stability
2.3 pts
Steady
Revenue to net income
Growth
2.9/10Revenue up 5.4% over 1 year, 6.3% a year over 5, EPS 16.5% a year over 5.
Revenue (trailing 12 months)
20.8Md USD
Revenue growth (1y)
5.44%
Moderate
Revenue growth (3y)
15.74%
Solid
EPS growth (1y)
-31.44%
Declining
EPS CAGR (5y)
16.45%
Exceptional
EPS revisions (3 months)
0.68%
Revised up
Valuation
5.8/10P/E 54.8x, forward P/E 35.0x, EV/EBITDA 13.2x, PEG 3.33. The multiple sits in the 18th percentile of its own 5-year history.
P/E (TTM)
54.8x
Expensive
Sector 28.9x|S&P 23.0x
Forward P/E
35.0x
Fair
EV / EBITDA
13.2x
Fair
Sector 16.0x|S&P 14.5x
PEG
3.33
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
174.19 USD
Fairly priced
P/E vs its own 5-year history
among the 18% lowest valuations
Far cheaper than usual
Market cap
49.7Md USD
Financial strength
4.4/10Cash covers 5.1% of the debt, net debt/EBITDA 3.4x.
Net debt / EBITDA
3.4x
Stretched
Gearing (net debt / equity)
65.30%
Tight
Cash
864M USD
Cash / market cap
1.74%
Stretched
Cash / total debt
5.14%
Stretched
Interest coverage
4.2x
Tight
Net debt
15.9Md USD
Equity
24.4Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 179.23 USD
- MM20183.22
- MM50177.07
- MM200170.95
- RSI 1446.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.42%
200-day average slope, 3 months
-2.80%
50-day average slope, 1 month
+8.54%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.37 % per day
Volatility change
-16.33%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.19 (3) | 12.62 (14) | 19 260 (4) | 5 628 (5) | 1 437 (4) |
| 2027 | 9.31 (3) | 13.29 (14) | 19 733 (12) | 5 759 (5) | 2 340 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 17, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 3 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 4 | ABT | 6.6 | 6.2 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 8 | SHL | 6.2 | 6.4 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 9 | BDX | 5.6 | 5.1 | 49.7Md USD | 54.8x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 24.7 % |
